A Lyophilized Form of Saccharomyces Boulardii Enhances the Helicobacter pylori Eradication Rates of Omeprazole-Triple Therapy in Patients With Peptic Ulcer Disease or Functional Dyspepsia

Authors

  • Nikolaos Kyriakos A' Department of Gastroenterology, Evangelismos Hospital, Athens, Greece.
  • Konstantinos Papamichael A' Department of Gastroenterology, Evangelismos Hospital, Athens, Greece.
  • Anastassios Roussos
  • Ioannis Theodoropoulos
  • Christos Karakoidas
  • Alexandros Smyrnidis
  • Emmanuel Archavlis
  • Konstantina Lariou
  • Gerassimos J Mantzaris

DOI:

https://doi.org/10.2015/hc.v8i3.538

Keywords:

Saccharomyces boulardii, Helicobater pylori infection, classic triple therapy, omeprazole, clarithromycin, amoxicillin

Abstract

Background: Saccharomyces boulardii prevents antibiotic-induced diarrhea and exerts anti-H.pylori effects in vitro and in vivo.

Aim: To assess whether S. boulardii enhances the efficacy of classic triple therapy in eradicating H. pylori.

Methods: Seventy patients with peptic ulcer or functional dyspepsia according to Rome III criteria and H. pylori infection were treated with omeprazole 20 mg bid, clarithromycin 500 mg bid and amoxicillin 1 g bid for 14 days. A total of 36 out of 70 (51%) patients were randomized to S. boulardii [Ultralevure®, two capsules tid for 14 days (group A) and 34 (49%) on no intervention (group B). H. pylori eradication was assessed by a 13C-Urea Breath Test.

Results: At baseline there were no significant differences between the two groups in any patient or disease characteristics. H. pylori was eradicated in 30/36 (83.4%) patients in group A vs 20/34 (58.8%) in group B (P=0.034, 95% CI 4.4% to 43.6%). Seven patients in group B (20.6%) and 1 patient in group A stopped treatment because of diarrhea (95% CI 3.3% to 32.7%, P=0.026). Multi-factorial analysis did not reveal any patient or disease related parameter linked to treatment outcome except for the use of the probiotic.

Conclusion: S. boulardii enhanced the effect of classic triple therapy mainly by preventing antibiotic- and/or proton pump inhibitor-induced diarrhea.

Downloads

Additional Files

Published

2013-06-09

Issue

Vol. 8 No. 3 (2013)

Section

ORIGINAL ARTICLES

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).